Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.41 |
| ▸ | OGA | O60502 | 2/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | WNT1 | P04628 | 2/20 | 0.36 |
| ▸ | GSK3B | P49841 | 2/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23684189 | 0.84 | HRH4 (0.43) | HRH3KDM4EALDH1A1PKM | |
| SCHEMBL23329535 | 0.83 | HRH3 (0.41) | HRH3OGAPIK3CAWNT1GSK3B | |
| SCHEMBL23304666 | 0.82 | HRH3 (0.37) | HRH3WNT1GSK3BDYRK1ADRD2 | |
| SCHEMBL23304301 | 0.82 | GBA1 (0.49) | PIK3CAHDAC4ALDH1A1 | |
| SCHEMBL23684245 | 0.81 | HTR2A (0.46) | PIK3CAKDM4EALDH1A1 | |
| SCHEMBL23684051 | 0.78 | CKS1B (0.48) | PIK3CAMAPT | |
| SCHEMBL23304591 | 0.76 | CKS1B (0.48) | KDM4EALDH1A1MAPT | |
| SCHEMBL23304314 | 0.75 | HRH4 (0.45) | HRH3 | |
| SCHEMBL30109094 | 0.71 | HRH3 (0.69) | HRH3OGA | |
| SCHEMBL1579769 | 0.70 | KDM4E (0.45) | HRH3PIK3CAKDM4EALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11986471-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2024-05-21 | — | — | US | disclosed |
| US-20230060499-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| US-20230054084-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2023-02-23 | — | — | US | disclosed |
| US-11077101-B1 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2021-08-03 | — | — | US | disclosed |
| WO-2021086879-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2021-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11986471-B2 | Compounds and methods of use | XDH, F12, LPXN | HRH3 183/4885OGA 3937/4885PIK3CA 3698/4885 |
| US-11077101-B1 | Compounds and methods of use | XDH, F12, LPXN | HRH3 183/4885OGA 3937/4885PIK3CA 3698/4885 |
| US-20230054084-A1 | COMPOUNDS AND METHODS OF USE | XDH, LPXN, F12 | HRH3 244/4885OGA 3998/4885PIK3CA 3771/4885 |
| US-20230060499-A1 | COMPOUNDS AND METHODS OF USE | XDH, F12, LPXN | HRH3 183/4885OGA 3937/4885PIK3CA 3698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.